anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Baseline procedures:

A parallel group design will be used for this study. Prior to the infusion trial, participants will reported to the laboratory on two separate occasions in the morning. On the first visit, we will determine participants' body weight and height as well as body composition by dual-energy X-ray absorptiometry. Finally, participants will be familiarized with unilateral leg extension and the ten repetition maximum (10RM) procedure. On a separate occasion, each subject will arrive to the lab after an overnight fast for the determination of oral glucose tolerance in response to the consumption of 75 g glucose dissolved in 500 mL of water. At the end of this visit, we will assess participant's unilateral 10RM for leg extension. In addition, participants will be instructed to refrain from vigorous physical activity and alcohol for three days prior to the tracer infusion.

Infusion protocol On the day of the infusion trial, participants will report to the laboratory at \~0700 h after a 10 h fast. An intravenous catheter will be inserted into an antecubital vein for baseline blood sample collection, after which a primed (2 μmol·kg-1), continuous infusion (0.05 μmol·kg Lean Body Mass-1·min-1) of L-\[ring-13C6\]phenylalanine will be initiated (t=-180 min) and maintained until the end of the trial. A second intravenous catheter placed in a contralateral dorsal hand vein will be placed in a heated blanket for repeated arterialized blood sampling. In the post-absorptive state, muscle biopsies of the vastus lateralis are to be collected at 0 min of infusion from a non-exercised control leg (CON). Subsequently, participants will perform moderate intensity unilateral leg extension exercise. Upon completion, participants will consume 170 g of lean ground pork (36 g protein). Additional muscle biopsies will be collected from both the exercised (EX) and CON legs at 120 and 300 min after pork ingestion. Arterialized blood samples will be collected every 30 or 60 min during the post-absorptive and postprandial-states and placed in pre-chilled EDTA tubes.
The prognosis of septic patients with cirrhosis is worse compared to septic patients without cirrhosis. Early and accurate prognosis determination in patients with cirrhosis and sepsis is pivotal for guiding treatment decisions. The aim of this study was to investigate the association between albumin-corrected anion gap (ACAG) and clinical prognosis of patients with sepsis and cirrhosis. This study extracted data of patients with sepsis and cirrhosis from the Medical Information Mart for Intensive Care (MIMIC-IV) database. A total of 1340 patients (64.6% male) were enrolled. After confounders adjusting, elevated ACAG had a significant association with 28-day mortality (HR1.604; 95% CI 1.258-2.048; P < 0.001). Restricted cubic spline revealed that a linear relationship between ACAG and 28-day mortality (P-nonlinear = 0.089, P-overall = 0.001). According to the ROC curve analysis, the ACAG demonstrated a higher area under the curve (AUC) of 0.703 compared to AG (0.675). Kaplan-Meier analysis revealed higher 28-day mortality in high ACAG group (log-rank test, χ^2 = 175.638, P < 0.001). Furthermore, subgroup analysis showed a significant interaction between ACAG and etiology of cirrhosis (P for interaction = 0.014). Therefore, ACAG could provide clinicians with valuable insights for guiding interventions in this high-risk population.
Neurodegenerative and demyelinating disease, such as multiple sclerosis (MS) are at the forefront of medical research and the discovery of new drugs and therapeutics. One phenomenon of degeneration seen in these diseases is transsynaptic degeneration (TSD), where damage from one axon spreads to the other axons that are connected to it synaptically. It has previously been found that demyelination occurs prior to neuronal loss in an experimental form of induced TSD. Retinoid-x receptor (RXR) agonists have been shown to promote remyelination. Therefore, this study aimed to reveal the effects of a novel endogenous RXR-γ agonist, 9-cis-13,14-dihydroretinoic acid (9CDHRA), on preventing or restoring the effects of TSD. 9CDHRA was administered to mice following optic nerve crush (ONC) procedures, and electrophysiology (visual evoked potential, VEP) and histological (immunofluorescent) assessments were performed. It was found that 9CDHRA treatment effectively delayed glial activation and reduced the presence of apoptosis at the site of injury and further anterogradely in the visual system, including the lateral geniculate nucleus (LGN) and primary visual cortex (V1). Most notably, 9CDHRA was able to maintain myelin levels following ONC, and effectively protected from demyelination. This was corroborated by VEP recordings with improved P1 latency. The promising findings regarding the injury attenuating and myelin protecting properties of 9CDHRA necessitates further investigations into the potential therapeutic uses of this compound.
Vascular access of the axillary vein will be performed using an ultrasound system (Siemens Acuson Freestyle) with a wireless vascular ultrasound probe (L8-3 or L13-5). One or more vascular punctures will be performed, as needed.
Background and Objectives: Patients undergoing chronic hemodialysis (HD) are predisposed to both thrombotic and bleeding complications due to the complex interplay of end-stage renal disease (ESRD), cardiovascular comorbidities, and the routine use of anticoagulant and antiplatelet therapies. This study aimed to investigate the incidence of bleeding and thrombotic events in chronic HD patients receiving anticoagulant and antiplatelet therapy, with a specific focus on those with atrial fibrillation (AF). Materials and Methods: A total of 224 patients, with 43 (19%) of them diagnosed with AF, were included in this single-center, observational cohort study conducted over 24 months. The cohort was divided into three groups: patients without anticoagulation, those on warfarin monotherapy, and those on combined warfarin and aspirin therapy. Bleeding events were classified as major, clinically relevant non-major bleeding (CRNMB), or minor bleeding, while thrombotic events included ischemic stroke, myocardial infarction, pulmonary embolism, and arteriovenous fistula thrombosis. Results: Overall, 35.7% of patients experienced a bleeding event, with major bleeding occurring in 9.4%. Patients with AF had significantly higher rates of major bleeding (18.6%) compared to those without AF (7.18%; p = 0.043), especially in the combined therapy group. Mortality due to bleeding was also higher in AF patients (14%). In contrast, thrombotic events occurred in 26.8% of patients, with AF patients experiencing significantly more events (48.8%) compared to non-AF patients (21.5%; p = 0.0006). The hazard ratio (HR) for major bleeding in patients on combined warfarin and aspirin therapy was 2.56 (p = 0.016), while the HR for thrombotic events was 2.34 (p = 0.0202). Conclusions: These findings highlight the increased risks of both bleeding and thrombosis in chronic HD patients with AF, particularly those on combined anticoagulation and antiplatelet therapy.
A composition comprising a dispersion of a bioadhesive containing polyvinyl pyrrolidone and a carboxy-functional polymer, and water is disclosed. The pH of the composition is controlled, preferably to about 6.0 or less, so that the bioadhesive is in a water-isoluble form. The bioadhesive is capable of binding water and other suitable ingredients, such as cosmetic or medical agents, to a mucosal membrane or the skin. If it is desirable to remove the composition, it may be washed away with ordinary tap water. Upon contact with tap water, the bioadhesive becomes water-soluble and loses its adhesive characteristics. A method of adhering the composition to the surfaces of a mucosal membrane or the skin is also disclosed.
A limited sub-study including 30 individuals enrolled in the primary study (not retrospective group) will incorporate serial blood draws relative to the vaccine doses. The purpose of the serologies and immunoassays is to explore the correlation an individual's development of a vaccine-induced immune response with changes in the continuous physiologic data surrounding the immunization process.
Provided is a method for classification of diseases including receiving image data associated with an image at a first resolution. The image may be processed, for example by removing a background from the image, deconstructing the image into separate layers, and segmenting the image to define a plurality of single-cell images. A single-cell image may be processed, for example, by applying a filter to the single-cell image to decrease a resolution of the single-cell image as compared to the first resolution, to a second resolution. A label may be assigned to the single-cell image. A machine learning model is trained to predict a classification of the single-cell image based on inputting a plurality of single-cell images into the model. The trained machine learning model may be used to predict the outcome of a treatment. Systems and computer program products are also provided.
Beginning on Day 1, subjects will receive the same dose and regimen of pegvaliase they were receiving in 165-302 or PAL-003 (pegvaliase dosing should continue without interruption from the previous study). Subsequent revisions to dosing regimens are allowed following consultation with the medical monitor.
Compsns for prophylaxis or treatment of herpes virus infections contain methenamine (I) and/or its derivs as active ingredient. (I) is active against herpes zoster and herpes simplex types I and II. The compsn may contain other active medicaments, vits., analgesics, chemotherapeutics and/or antibiotics. Derivs of (I) include salts with org. or (in)org. acids cpds with salts such as MgCl2, CaCl2 or Na acetate or cpd with nonacidic org. cpds such as CH3Cl. The dose is generally 1g (I) 2-3 times/day and should not excess 6g/day.
This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
A disposable fluid container (20) comprises an integrated pump motive assembly (50) for pumping fluid from an interior of the container. In some example embodiments, the integrated pump motive assembly (50) is situated at least partially within the container housing, e.g., at least partially or even completely submerged inside a fluid reservoir (30) defined by the container housing (22). In other example embodiments, the pump motive assembly is outside the fluid reservoir (30), yet still integrally formed with the container. In yet other embodiments, the pump motive assembly is in a lid (194) of the container. As one aspect of this disposable pump-integrated container technology, the pump motive assembly comprises a displaceable electrodynamic actuator, such as (for example) piezoelectric diaphragm pump, taking any of various configurations. As another and distinct aspect of this disposable pump- integrated container technology, the pump motive assembly is connected via an electrical lead (78) and/or terminal (80) to receive pump driving signals from outside the container.
Participants received fosaprepitant dimeglumine once daily (QD) for 3 days and were followed for 14 days during the 17-day Cycle 1. Participants also optionally received dexamethasone as background therapy, and a serotonin (5-hydroxytryptamine \[5-HT3\]) receptor antagonist on Day 1 and optionally on Days 2-3 as background therapy. After completing Cycle 1, participants had the option to continue for up to 2 additional 17-day cycles of the same treatment regimen.
The invention discloses an extraction method of L-citrulline in seed melon. The method comprises the steps of ultrafiltration liquid preparation, column elution, reduced-pressure distillation and crystallization. The invention also discloses an application of L-citrulline extracted with the above method. Specifically, materials with needed weight are prepared into acid particles and alkali particles; the particles are dried, and a lemon essence is sprayed in; the particles are dried, and are well mixed with polyethylene glycol 6000; and the mixture is tableted, such that L-citrulline effervescent tablets are obtained. The extraction method provided by the invention has the advantages of simple preparation process, low cost, low energy consumption, and low waste and pollutant production. The effervescent tablets prepared with the extracted L-citrulline have the advantages of fast disintegration, good effervescent effect, good sweet and sour taste, and convenient application. With the methods provided by the invention, a novel approach for comprehensively developing and utilizing seed melons is provided.
NON-OPC/p16-NEGATIVE OPC: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive high-dose cisplatin IV Q3W (on days 1, 22, and 43) during radiation therapy in the absence of disease progression or unacceptable toxicity.
Dose-escalation cohort 3: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).
Disclosed is a radiological imaging device, which comprises a radiation emission source, a radiation receiver, an auxiliary optical system and a database. The radiation emission source emits a radiation to an inspected animal. The radiation receiver receives the radiation penetrating the inspected animal. The auxiliary optical system comprises at least one image capture device and a processing device coupled to the image capture device. The image capture device acquires a stereoscopic image of the inspected animal. The stereoscopic image displays a first posture of the inspected animal. The database is coupled to the processing device and stores a plurality of ideal postures corresponding to different animals and different inspection items. The processing device compares the first posture of the stereoscopic image with these ideal postures to determine whether the first posture is compliant with the regulation for ideal postures of radiological imaging. The inspected animal may adjust the first posture to a second posture according to the suggestion of the comparison result from comparison.
Patients receive guadecitabine SC QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive DLI IV over 10-30 minutes on day 6 of cycles 2, 4, and 6 in the absence of disease progression or unacceptable toxicity.
Radiotherapy: The total radiation dose is 52.2Gy (1.8Gy fractions). Chemotherapy: Nimotuzumab, given during radiotherapy, is administered via intravenous drip with a dosage of 150mg/m2, weekly, for 6 consecutive weeks. After radiotherapy and evaluation, disease progression-free patients will continue to receive Nimotuzumab treatment biweekly until disease relapse or progression. Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation therapy are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles.
This group receives standard preoperative physiotherapy education as well a home-exercise instructions. They will also receive 3-4 home visits by physiotherapists between recruitment and surgery, to conduct exercises in their homes.
FIELD: medicine. SUBSTANCE: preparation has Klopidogrel and Aspirin as active agent introduced in unbound state or as pharmaceutically acceptable salts. Molar proportion of Aspirin/Klopidogrel is equal to 2.5 to 11.5. Klopidogrel and Aspirin are administered as oral or parenteral applications. EFFECT: enhanced effectiveness of treatment; improved synergetic action. 13 cl, 2 tbl
Patients receive leflunomide PO QD for days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may optionally continue leflunomide for an additional 6 cycles as long as response or stable disease is maintained.
Blood vessels in tumors are often dysfunctional. This impairs the delivery of therapeutic agents to and distribution among the cancer cells. Subsequently, treatment efficacy is reduced, and dose escalation can increase adverse effects on non-malignant tissues. The dysfunctional vessel phenotypes are attributed to aberrant pro-angiogenic signaling, and anti-angiogenic agents can ameliorate traits of vessel dysfunctionality. However, they simultaneously reduce vessel density and thereby impede drug delivery and distribution. Exploring possibilities to improve vessel functionality without compromising vessel density in the tumor microenvironment, we evaluated transcription factors (TFs) involved in epithelial-mesenchymal transition (EMT) as potential targets. Based on similarities between EMT and angiogenic activation of endothelial cells, we hypothesized that these TFs, Snai1 in particular, might serve as key regulators of vessel dysfunctionality. In vitro, experiments demonstrated that Snai1 (similarly Slug and Twist1) regulates endothelial permeability, permissiveness for tumor cell transmigration, and tip/stalk cell formation. Endothelial-specific, heterozygous knock-down of Snai1 in mice improved vascular quality in implanted tumors. This resulted in better oxygenation and reduced metastasis. Notably, the tumors in Snai1KD mice responded significantly better to chemotherapeutics as drugs were transported into the tumors at strongly increased rates and more homogeneously distributed. Thus, we demonstrate that restoring vessel homeostasis without affecting vessel density is feasible in malignant tumors. Combining such vessel re-engineering with anti-cancer drugs allows for strategic treatment approaches that reduce treatment toxicity on non-malignant tissues.
The invention discloses a traditional Chinese medicine composition for treating phlegm-dampness stagnation type fatty liver. Fatty liver equivalently belongs to the category of 'accumulation', 'phlegm', 'hypochondriac pain' and the like in traditional Chinese medicine. The pathogenesis of the fatty liver can be summarized as follows: liver dysfunction, liver blood stasis, dysfunction of the spleen in transport, non-dispelling of damp evil, internal phlegm turbidity, dysfunction of kidney for activation of Qi and phlegm stagnation. The phlegm-dampness stagnation type fatty liver is caused by qi stagnation and blood stasis due to long-time phlegm-damp accumulation. The traditional Chinese medicines which include cremanthodium, ligularia sibirica, fomitopsis officinalis ames, saltliving wormwood leaves, beautiful galangal fruit, phellandrium, trema cannabina, water spinach root, triptophenolide and flos rosae rugosae and have the effects of eliminating phlegm and dispelling dampness as well as soothing the liver and regulating qi-flowing for strengthening the spleen are selected; the traditional Chinese medicines are decocted with water into a decoction by a preparation room. Clinical tests show that the total effective rate reaches 97.5% and is obviously better than 78.9% of a control group, and the traditional Chinese medicine composition is worth of clinical popularization and application.
BACKGROUND & AIMS: The pancreas is composed of endocrine and exocrine parts, and its interlacing structure indicates potential interaction between endocrine and exocrine cells. Although the tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) has been well characterized, the role of pancreatic endocrine cells during carcinogenesis is relatively understudied.
METHODS: The changes of endocrine cells in PDAC by single-cell transcriptome sequencing, spatial transcriptome sequencing, and multiplex immunohistochemistry were depicted. After that, the interaction between pancreatic carcinogenesis and endocrine changes was explored in orthotopic transplantation mice, KrasLSL-G12DPdx1-Cre mice, and KrasLSL-G12Dp53LoxPPdx1-CreER mice. Finally, we proved the mechanism of the interaction between endocrine and exocrine parts of the pancreas through islet isolation, co-culture in vitro and co-injection in vivo.
RESULTS: Pancreatic endocrine cells displayed significantly different transcriptomic characteristics and increased interaction with exocrine part in PDAC. Specifically, among all of the changes, pancreatic polypeptide-positive cells showed a sharp increment accompanied by the progression of the cancer lesion, which might be derived from the transdifferentiation of α and β cells. Interestingly, it was proved that PDAC cells were able to induce the transdifferentiation of pancreatic α cells and β cells into glucagon-pancreatic polypeptide and insulin-pancreatic polypeptide double-positive cells, which further promoted carcinogenesis and development of PDAC in a paracrine-dependent manner and formed a reciprocal interaction.
CONCLUSIONS: This study systematically maps the alteration of pancreatic endocrine cells in PDAC and elucidates the potential endocrine-exocrine interaction mechanisms during PDAC carcinogenesis. In addition, cancer-associated endocrine cells are defined and characterized, thereby further broadening the composition of PDAC microenvironment.
This study will be a parallel-group randomized control trial with a 1:1 allocation ratio. Consecutive, eligible patients admitted to 4 ICUs in Calgary, Alberta, Canada with at least one family member present will be identified by discussion with the most responsible attending physician and bedside nurse. All eligible and consenting family members will receive standard care, which is an informational pamphlet on ICU delirium presented to all patients and families upon admission. Participants in both the intervention and control groups will also complete a demographics questionnaire, the Critical Care Family Needs Inventory (CCFNI), the Barriers to Care Questionnaire in the ICU (BCQ-ICU), the Caregiver Coping Strategies (CSS) questionnaire, and the Caregiver ICU Delirium Knowledge Questionnaire (CIDKQ) upon enrollment. Additionally, all family members will complete the Delirium Burden (DEL-B) questionnaire, Kessler Psychological Distress Scale (KPDS-10), Patient Health Questionnaire 9 (PHQ-9), Generalized Anxiety Disorder 7 (GAD-7) daily for a maximum of five days.

Family members randomized to the intervention group will receive additional ICU delirium education, whereas the control group will not. The intervention includes components of delirium education, prevention/management and detection. Family members will receive education by watching a 6-minute education video or reading an education booklet with a trained research assistant on the signs of delirium, who is at risk, and what they can do to prevent and manage it. They will practice identifying delirium with the Sour Seven questionnaire using previously validated case vignettes of hypothetical ICU patients. Delirium prevention and management will include a daily checklist of non-pharmacological interventions to be completed by the family member. This will include an orientation protocol (e.g., provide visual and hearing aids, orientation of day/time/location, familiar objects from home, television during the day with daily news, non-verbal music), mobility protocol (cognitive activities depending on the patient's ability), and an environmental protocol (lights off at night and on during the day, ear plugs, noise reduction during the night). In addition to non-pharmacological delirium prevention and management, this list will have a checkbox indicating if the family caregiver notified any member of the bedside care team about symptoms of delirium.

Family members in both intervention and control groups will also complete follow-up questionnaires at 1-month and 3-months through an online link to a REDCap survey. These questionnaires will include the Family Satisfaction for the Intensive Care Unit (FSICU), KPDS-10, GAD-7, PHQ-9, and CIDKQ .